ProSomnus® Sleep Technologies to Participate at the Oppenheimer Private Company Showcase
05 Outubro 2022 - 10:00AM
ProSomnus Holdings Inc. (“ProSomnus”), the leader in patient
preferred medical devices for the treatment of obstructive sleep
apnea (OSA), today announced that Laing Rikkers, Executive
Chairwoman and Co-Founder, is scheduled to participate at the
Oppenheimer Private Company Showcase on October 17-18, 2022 at the
Four Seasons in Palo Alto, California. Laing Rikkers will present
at 10:25 am Pacific Time, and will be available for investor
meetings throughout both days.
About ProSomnusProSomnus is the first
manufacturer of precision, mass-customized oral appliance therapy
devices to treat OSA, which affects over 74 million Americans and
is associated with serious comorbidities, including heart failure,
stroke, hypertension, morbid obesity and type 2 diabetes.
ProSomnus’s patented devices are a more comfortable and less
invasive alternative to Continuous Positive Airway Pressure (CPAP)
therapy, and lead to more effective and patient-preferred outcomes.
With more than 150,000 patients treated, ProSomnus’s devices are
the most prescribed oral appliance therapy in the U.S. To learn
more, visit www.ProSomnus.com.
In May 2022, ProSomnus entered a definitive merger agreement
with Lakeshore Acquisition I Corp. (Nasdaq: LAAA), a special
purpose acquisition company. Upon closing, the combined company is
expected to change its name to ProSomnus, Inc. and its Class A
common stock is expected to be traded on the Nasdaq Capital Market
under the symbol “OSA”.
Contacts
MediaSean LeousSean.Leous@westwicke.com
InvestorsMike
CavanaughMike.Cavanaugh@westwicke.com
Lakeshore Acquisition I (NASDAQ:LAAA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Lakeshore Acquisition I (NASDAQ:LAAA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Lakeshore Acquisition I Corporation da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de